Benefit-Risk Profile of DAPT Continuation Beyond 1 Year after PCI in Patients with High Thrombotic Risk Features as Endorsed by 2018 ESC/EACTS Myocardial Revascularization Guideline.
Hao-Yu WangKe-Fei DouYang WangDong YinBo XuRun-Lin GaoPublished in: Cardiovascular drugs and therapy (2020)
Among patients with ESC-endorsed HTR who were free from major ischemic or bleeding events 1 year after coronary stenting, continued DAPT beyond 1 year might offer better effectiveness in terms of atherothrombotic events and comparable safety in terms of clinically relevant bleeding compared with ≤ 1-year DAPT. ESC-HTR criteria is an important parameter to take into account in tailoring DAPT prolongation.
Keyphrases
- antiplatelet therapy
- percutaneous coronary intervention
- acute coronary syndrome
- coronary artery disease
- atrial fibrillation
- st segment elevation myocardial infarction
- acute myocardial infarction
- coronary artery bypass grafting
- st elevation myocardial infarction
- randomized controlled trial
- systematic review
- coronary artery
- left ventricular
- ischemia reperfusion injury
- heart failure
- oxidative stress
- cerebral ischemia
- coronary artery bypass
- blood brain barrier